Johnson & Johnson $JNJ Holdings Reduced by Martingale Asset Management L P

Martingale Asset Management L P lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 7.0% during the 1st quarter, Holdings Channel.com reports. The fund owned 256,191 shares of the company’s stock after selling 19,152 shares during the quarter. Johnson & Johnson makes up approximately 1.1% of Martingale Asset Management L P’s portfolio, making the stock its 10th largest holding. Martingale Asset Management L P’s holdings in Johnson & Johnson were worth $42,487,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Lantz Financial LLC grew its stake in shares of Johnson & Johnson by 3.3% during the 1st quarter. Lantz Financial LLC now owns 11,974 shares of the company’s stock valued at $1,986,000 after purchasing an additional 377 shares during the period. Sulzberger Capital Advisors Inc. purchased a new position in shares of Johnson & Johnson in the fourth quarter worth approximately $453,000. Joel Isaacson & Co. LLC grew its position in Johnson & Johnson by 3.5% during the first quarter. Joel Isaacson & Co. LLC now owns 74,132 shares of the company’s stock valued at $12,294,000 after buying an additional 2,526 shares during the period. State of Wyoming increased its holdings in Johnson & Johnson by 205,580.0% during the fourth quarter. State of Wyoming now owns 10,284 shares of the company’s stock valued at $1,487,000 after buying an additional 10,279 shares during the last quarter. Finally, Tokio Marine Asset Management Co. Ltd. raised its position in Johnson & Johnson by 7.0% in the first quarter. Tokio Marine Asset Management Co. Ltd. now owns 73,350 shares of the company’s stock worth $12,164,000 after acquiring an additional 4,816 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Price Performance

NYSE:JNJ opened at $178.5890 on Thursday. The business’s 50-day simple moving average is $162.59 and its two-hundred day simple moving average is $158.87. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $180.61. The stock has a market cap of $430.10 billion, a PE ratio of 19.10, a P/E/G ratio of 2.26 and a beta of 0.41. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, July 16th. The company reported $2.77 earnings per share for the quarter, topping analysts’ consensus estimates of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts forecast that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a dividend yield of 2.9%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 55.61%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Bank of America boosted their price objective on shares of Johnson & Johnson from $161.00 to $175.00 and gave the company a “neutral” rating in a research report on Thursday, July 17th. UBS Group boosted their price target on Johnson & Johnson from $180.00 to $190.00 and gave the company a “buy” rating in a report on Thursday, July 17th. Wall Street Zen downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, July 18th. Guggenheim reaffirmed a “neutral” rating and set a $167.00 price objective (up from $164.00) on shares of Johnson & Johnson in a research report on Thursday, July 17th. Finally, Royal Bank Of Canada increased their target price on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an “outperform” rating in a report on Thursday, July 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $174.50.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.